Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia -

Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia
Information type: Randomised controlled trials
Source: Neuropsychopharmacology
Specialities: Later life | Mental health and illness | Neurological disorders
Summary
Encenicline 0.27 mg was associated with significant improvements vs placebo in general cognitive function (p=0.034) in the primary efficacy end point of CogState Overall Cognition Index (OCI) score in this phase II study of 307 patients.
UKMi comment
Encenicline is an orally bioavailable nicotinic alpha-7 agonist currently in development for Alzheimer’s disease and schizophrenia.
Related links: